Reposted by Valerie van de Velde
“These results are among the most promising we have seen in this field so far and clearly warrant progressing to a confirmatory Phase III trial”.
Hoopvolle resultaten van een Fase II studie naar de werking van Bezisterim voor (ook ernstige) Long Covid patienten!
🙏🙏🙏🙏
markets.businessinsider.com
BioVie Announces Topline Results from Phase 2 ADDRESS‑LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
Statistically significant benefits observed in bezisterim-treated Long COVID patients in pre-specified subgroups with high baseline fatigue, cogni...